1066
J. Lee et al. / Bioorg. Med. Chem. Lett. 10 (2000) 1063±1066
toni-Kaplan, M.; Mckenna, D. G.; Wasicak, J. T.; Holladay,
References and Notes
M. W.; Williams, M.; Arneric, S. P. J. Pharmacol. Exp. Ther.
1998, 285, 777.
1. (a) Spande, T. F.; Garrao, H. M.; Edwards, M. W.; Yeh,
H. J. C.; Pannel, L.; Daly, J. W. J. Am. Chem. Soc. 1992, 114,
3475. (b) Li, T.; Qian, C.; Eckman, J.; Huang, D. F.; Shen, T.
Y. Bioorg. Med. Chem. Lett. 1993, 3, 2759. (c) Badio, B.; Daly,
J. W. Mol. Pharmacol. 1994, 45, 563. (d) Fisher, M.; Huangfu,
D.; Shen, T. Y.; Guyenet, P. G. J. Pharmacol. Exp. Ther.
1994, 270, 702.
4. (a) McDonald, I. A.; Vernier, J.-M.; Cosford, N.; Corey-
Naeve, J. Curr. Pharmaceut. Des. 1996, 2, 357. (b) Damaj, M.
I.; Glassco, W.; Dukat, M.; May, E. L.; Glennon, R. A.;
Martin, B. R. Drug Develop. Res. 1996, 38, 177. (c) Glassco,
W.; May, E. L.; Weaver, V.; Damaj, M. I.; Rosecrans, J.;
Martin, B. R. Med. Chem. Res. 1994, 4, 474.
2. Bai, D.; Xu, R.; Zhu, X. Drugs Future 1997, 22, 1210.
3. (a) Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Cur-
zon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R.
S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.;
Arneric, S. P. Science 1998, 279, 77. (b) Holladay, M. W.;
Wasicak, J. T.; Lin, N.-H.; He, Y.; Ryther, K. B.; Bannon, A.
W.; Buckley, M. J.; Kim, D. J. B.; Decker, M. W.; Anderson,
D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts,
D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.;
Arneric, S. P. J. Med. Chem. 1998, 41, 407. (c) Holladay, M.
W.; Bai, H.; Li, Y.; Lin, N-H.; Daanen, J. F.; Ryther, K. B.;
Wasicak, J. T.; Kincaid, J. F.; He, Y.; Hettinger, A.-M.;
Huang, P.; Anderson, D. J.; Bannon, A. W.; Buckley, M. J.;
Campbell, J. E.; Donnelly-Roberts, D. L.; Gunther, K. L.;
Kim. D. J. B.; Kuntzweiler, T. A.; Sullivan, J. P.; Decker, M.
W.; Arneric, S. P. Bioorg. Med. Chem. Lett. 1998, 8, 2797. (d)
Decker, M. W.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.;
Holladay, M. W.; Ryther, K. B.; Lin, N.-H.; Wasicak, J. T.;
Williams, M.; Arneric, S. P. Eur. J. Pharmacol. 1998, 346, 23.
(e) Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler,
T. A.; Briggs, C. A.; Anderson, D. J.; Campbell, J. E.; Piat-
5. 3-Pyrrolidinol, (R)-(+)-pyrrolidinol, 3-hydroxypiperidine,
and 1-methyl-3-pyrrolidinol were purchased from Aldrich.
(S)-( )-Pyrrolidinol was purchased from Synthon. 1-Ethyl, 1-
ethyl-3-pyrrolidinols were purchased from TCI America. 1-
(Diphenylmethyl)-3-hydroxyazetidine was purchased from the
Maybridge Chemical Company.
6. Mitsunobu, O. Synthesis 1981, 1.
7. (a) Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron
Lett. 1975, 4467. (b) Sakamoto, T.; Shiraiwa, M.; Kondo, Y.;
Yamanaka, H. Synthesis 1983, 312.
8. (a) Stille, J. K.; Groh, B. L. J. Am. Chem. Soc. 1987, 109,
813. (b) Stille, J. K. Angew. Chem., Int. Ed. Engl. 1986, 25, 508.
9. Recently Lin and co-workers reported the synthesis of (R)
and (S)-(3-(1-methyl-3-pyrrolidinyl)oxy)pyridine with Ki of
4.44 and 2.67 nM, respectively. Lin, N-H.; Abreo, M. A.;
Gunn, D. E.; Lebold, S. A.; Lee, E. L.; Wasicak, J. T.; Het-
tinger, A-H.; Daanen, J. F.; Garvey, D. S.; Campbell, J. E.;
Sullivan, J. P.; Williams, M. W.; Arneric, S. P. Bioorg. Med.
Chem. Lett. 1999, 9, 2747.
10. The binding assay was performed according to Pabreza, L.
A.; Dhawan, S.; Kellar, K. J. Mol. Pharmacol. 1991, 39, 9.